Valuation: CSPC Pharmaceutical Group Limited

Market Cap 99.35B 12.66B 10.93B 10.28B 9.35B 17.57B 1,211B 17.86B 120B 47.07B 606B 47.53B 46.5B 2,015B P/E 2026 *
11.7x
P/E 2027 * 14.4x
Enterprise Value 89.01B 11.34B 9.8B 9.21B 8.37B 15.74B 1,085B 16B 108B 42.17B 543B 42.59B 41.66B 1,805B EV / Sales 2026 *
2.46x
EV / Sales 2027 * 2.46x
Free-Float
67.42%
Yield 2026 *
4.57%
Yield 2027 * 4.2%
Aug. 11 CSPC Pharma Starts Phase 1 Trial of CAR-T Drug for Relapsed, Refractory Lupus MT
Aug. 10 CSPC Pharmaceutical's Mpox Vaccine Candidate Gets Trial Approval from US FDA MT
Aug. 05 CSPC Pharma Gets $10 Million Milestone Payment from AstraZeneca Under Research Deal MT
Aug. 05 CSPC Pharma, AstraZeneca Form JV to Build Biologics Manufacturing Facility in China MT
Aug. 05 CSPC Pharmaceutical Group Limited Announces Receipt of USD 10 Million Milestone Payment Under the Strategic Research Collaboration Agreement with Astrazeneca CI
Aug. 05 CSPC Pharmaceutical Group Limited And AstraZeneca Enter Into Joint Venture Contract For Establishment Of Joint Venture To Further Deepen Strategic Collaboration CI
Aug. 04 CSPC Pharma Unit, Alphamab Oncology's Breast Cancer Drug Application Granted Priority Review in China MT
Aug. 04 CSPC Pharmaceutical Group Limited New Drug Application For Anbenitamab And Docetaxel For Injection (Albumin-Bound) For Neoadjuvant Treatment Accepted By The NMPA CI
Aug. 03 CSPC Pharma Begins Phase Ib/II Trial of Colorectal Cancer Drug Candidate MT
Aug. 03 CSPC Pharmaceutical Group Limited Initiates Phase Ib/II Clinical Trial Of SYS6090 Injection For Treatment Of Colorectal Cancer CI
Aug. 02 CSPC Pharma Wins China Trial Approval for RSV Vaccine MT
Jul. 31 CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial Of SYS6041 as Combination Therapy for Treatment of Recurrent Ovarian Cancer At First Centre in China CI
Jul. 31 CSPC Pharmaceutical Group Limited Announces Recombinant Respiratory Syncytial Virus Vaccine SYS6057 Obtains Clinical Trial Approval In China CI
1 day-1.81%
Current month+1.28%
1 month+3.08%
3 months+11.70%
6 months-14.05%
Current year+3.08%
1 week 8.52
Extreme 8.52
9.22
1 month 7.97
Extreme 7.97
9.22
Current year 6.53
Extreme 6.53
10.96
1 year 6.53
Extreme 6.53
11.63
3 years 4.27
Extreme 4.27
11.63
5 years 4.27
Extreme 4.27
11.9
10 years 3.61
Extreme 3.609374
13.93
Manager TitleAgeSince
Chief Executive Officer 46 2025-12-18
Chief Operating Officer 56 2025-12-18
Corporate Officer/Principal 44 2024-06-30
Director TitleAgeSince
Chairman 72 2011-08-25
Director/Board Member 56 2012-01-19
Director/Board Member 66 2012-12-20
Date Insider Type Main position Quantity % Market Cap.
6/23/26 Other

Director

-700,000 0.0061%
12/23/25 Other

Chairman

6,706,000 0.0582%
11/25/25 Other

Chairman

10,300,000 0.0894%
Change 5-day change 1-year change 3-year change Capi.($)
-1.81%0.00%-20.71%+48.55% 12.66B
-2.25%-0.47%+68.30%+115.90% 1,052B
-0.66%+0.43%+47.39%+50.54% 627B
-0.54%+1.39%+20.69%+63.99% 441B
-1.99%-3.32%+38.71%+35.41% 349B
-1.05%-2.81%+23.07%+35.70% 287B
-2.12%-3.67%-1.14%+5.37% 241B
-0.63%+1.04%+40.05%+56.09% 224B
-1.19%-3.41%-9.57%-52.71% 202B
+0.16%+3.87%+16.89%+73.73% 172B
Average -1.21%+0.72%+22.37%+43.26% 360.78B
Weighted average by Cap. -1.36%+0.23%+38.88%+61.24%

Financials

2026 *2027 *
Net sales 36.14B 4.61B 3.98B 3.74B 3.4B 6.39B 440B 6.5B 43.8B 17.13B 221B 17.29B 16.92B 733B 35.13B 4.48B 3.87B 3.63B 3.3B 6.21B 428B 6.31B 42.57B 16.64B 214B 16.81B 16.44B 712B
Net income 8.29B 1.06B 913M 858M 780M 1.47B 101B 1.49B 10.05B 3.93B 50.61B 3.97B 3.88B 168B 6.84B 872M 753M 708M 644M 1.21B 83.39B 1.23B 8.29B 3.24B 41.76B 3.27B 3.2B 139B
Net Debt -10.34B -1.32B -1.14B -1.07B -973M -1.83B -126B -1.86B -12.53B -4.9B -63.11B -4.95B -4.84B -210B -13.09B -1.67B -1.44B -1.35B -1.23B -2.31B -159B -2.35B -15.86B -6.2B -79.86B -6.26B -6.13B -265B
Logo CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.
Employees
19,700
Date Price Change Volume
26-08-14 HK$8.690 -1.81% 39,418,434
26-08-13 HK$8.850 +2.02% 105,733,552
26-08-12 HK$8.675 -0.29% 50,923,111
26-08-11 HK$8.700 +0.87% 72,200,336
26-08-10 HK$8.625 -0.75% 86,457,309
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
8.690HKD
Average target price
11.72HKD
Spread / Average Target
+34.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 1093 Stock